Hypoxia-inducible transcription factor (HIF)-1α stabilization by actin-sequestering protein, thymosin beta-4 (TB4) in Hela cervical tumor cells

被引:53
作者
Oh, Jin-Mi [1 ]
Ryoo, In-Ja [2 ]
Yang, Young [3 ]
Kim, Hyun-Sun [1 ]
Yang, Kyu-Hwan [4 ]
Moon, Eun-Yi [1 ]
机构
[1] Sejong Univ, Dept Biosci & Biotechnol, Seoul 143747, South Korea
[2] KRIBB, Dept Funct Metabolom, Taejon 305806, South Korea
[3] Sookmyung Womens Univ, Dept Life Sci, Res Ctr Womens Dis, Seoul 140742, South Korea
[4] Kyungwon Univ, Gachon Bionano Res Inst, Kyunggido 461701, South Korea
关键词
thymosin beta-4; hela cell; hypoxia; HIF-1; alpha; ERK;
D O I
10.1016/j.canlet.2008.01.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Thymosin beta-4 (TB4) is an actin-sequestering protein to control cytoskeletal reorganization. Here, we investigated whether TB4 proteins (TB4P) affect tumor microenvironment by measuring hypoxia-inducible transcription factor (HIF)-1 alpha stabilization in cervical tumor cells, since TB4P reduced paclitaxel-induced cell death rate. TB4P increased HIF-1 alpha stabilization and transactivation, which is measured by the increase of hypoxia response element (HRE)-luciferase activity and target gene, vascular endothelial growth factor (VEGF) transcription. TB4P also elevated ERK phosphorylation. PD98059, ERK inhibitor reduced HIF-1 alpha increased by TB4P. Paclitaxel-induced cell death was inhibited by hypoxia conditioning that increased HIF-1 alpha stabilization and ERK phosphorylation. PD98059 reversed paclitaxel-induced cell death which was attenuated by hypoxia. Collectively, TB4P could lead tumor cell microenvironment to hypoxia condition, which might be resulted in antitumor drug-resistance induction. It suggests that soluble TB4P could be a novel target to control tumor cell death by regulating tumor cell microenvironment. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:29 / 35
页数:7
相关论文
共 36 条
[1]
Brown JM, 1999, CANCER RES, V59, P5863
[2]
Role of thymosin β4 in tumor metastasis and angiogenesis [J].
Cha, HJ ;
Jeong, MJ ;
Kleinman, HK .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (22) :1674-1680
[3]
HIF gene expression in cancer therapy [J].
Chan, Denise A. ;
Krieg, Adam J. ;
Turcotte, Sandra ;
Giaccia, Amato J. .
OXYGEN BIOLOGY AND HYPOXIA, 2007, 435 :323-+
[4]
Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor [J].
Cho, WK ;
Seong, YR ;
Lee, YH ;
Kim, MJ ;
Hwang, KS ;
Yoo, J ;
Choi, S ;
Jung, CR ;
Im, DS .
MOLECULAR THERAPY, 2004, 10 (05) :938-949
[5]
RAPID COLORIMETRIC ASSAY FOR CELL-GROWTH AND SURVIVAL - MODIFICATIONS TO THE TETRAZOLIUM DYE PROCEDURE GIVING IMPROVED SENSITIVITY AND RELIABILITY [J].
DENIZOT, F ;
LANG, R .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 89 (02) :271-277
[6]
Coupling of folding and binding of thymosin β4 upon interaction with monomeric actin monitored by nuclear magnetic resonance [J].
Domanski, M ;
Hertzog, M ;
Coutant, J ;
Gutsche-Perelroizen, I ;
Bontems, F ;
Carlier, MF ;
Guittet, E ;
van Heijenoort, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (22) :23637-23645
[7]
WHAT IS THE EVIDENCE THAT TUMORS ARE ANGIOGENESIS DEPENDENT [J].
FOLKMAN, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (01) :4-6
[8]
Arsenite induces HIF-1α and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells [J].
Gao, N ;
Shen, LQ ;
Zhang, Z ;
Leonard, SS ;
He, HJ ;
Zhang, XG ;
Shi, XL ;
Jiang, BH .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2004, 255 (1-2) :33-45
[9]
Thymosin β4:: A new molecular target for antitumor strategies [J].
Goldstein, AL .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (22) :1646-1647
[10]
Inhibitory effect of peroxiredoxin II (Prx II) on Ras-ERK-NFκB pathway in mouse embryonic fibroblast (MEF) senescence [J].
Han, Ying-Hao ;
Kwon, Jeong-Hoon ;
Yu, Dae-Yeul ;
Moon, Eun-Yi .
FREE RADICAL RESEARCH, 2006, 40 (11) :1182-1189